From Suppression to Control Through Microbiome and Sebum Normalisation

Blending Dermatology with Aesthetics – A Smart Proposition for a Thriving Medical Aesthetic Business

Seborrhoeic dermatitis is one of the most common yet persistently misunderstood dermatological conditions encountered in clinical practice.

In the UK alone, it is estimated that over 2.5 million individuals over the age of 35 are affected, many of whom cycle repeatedly through treatments without achieving sustained control.

It is frequently described and therefore managed as a fungal disorder, but this description, while convenient, is incomplete.

Because seborrhoeic dermatitis is not simply an issue of Malassezia overgrowth. It is a disorder of sebaceous activity, microbiome imbalance, and inflammatory response, interacting within a dynamic and self-perpetuating system.

When viewed through this lens, the limitations of traditional treatment approaches become clear.

The Problem with Conventional Thinking

Most treatment strategies for seborrhoeic dermatitis focus on suppression. Antifungals aim to reduce yeast populations. Topical steroids reduce inflammation. Keratolytics remove visible scaling.

Each of these can be effective in isolation, particularly in the short term. But none of them restore the underlying system.

As a result, the condition often follows a familiar pattern: improvement, withdrawal of treatment, relapse, and escalation.

Understanding the Seborrhoeic System

Seborrhoeic dermatitis arises from the interaction of several key factors:

• Altered sebum production and composition
• Proliferation of Malassezia species and associated microbial imbalance
• Enzymatic breakdown of lipids into pro-inflammatory fatty acids
• Activation of inflammatory pathways and disruption of the skin barrier
• Accelerated keratinocyte turnover and visible desquamation

These elements do not act independently. They form a closed loop, where each reinforces the other.

This is why treating a single component rarely produces durable results. To achieve control, the loop itself must be addressed.

Closebax: A Different Approach

Closebax has been developed not as a conventional antifungal or keratolytic, but as a system designed to operate within this biological framework.

Its role is not to strip the skin or suppress it aggressively, but to rebalance the environment in which seborrhoeic dermatitis develops.

This includes:

• Modulation of the cutaneous microbiome rather than indiscriminate eradication
• Support of normal sebum composition and reduction of pro-inflammatory lipid breakdown
• Attenuation of inflammatory signalling without compromising barrier integrity
• Normalisation of desquamation through restoration of epidermal turnover

The distinction is subtle in description, but profound in practice.

Because rather than repeatedly interrupting the condition, Closebax allows the clinician to begin stabilising it.

Safety and Tolerability Across All Age Groups

One of the most significant challenges in managing seborrhoeic dermatitis is the need for long-term, often lifelong, control. This immediately raises the question of safety.

• Steroids are effective, but not suitable for prolonged use, particularly on the face.
• Antifungals can be useful, but may irritate and do not address the full pathway.#
• More aggressive approaches risk compromising the skin barrier.

Closebax occupies a different position.

It is not steroid, non-antibiotic, and barrier-respecting, making it suitable not only for adult patients, but also for children and even infants, where seborrhoeic conditions such as cradle cap are common.

This is a major plus advantage.

It allows for continuity of care across age groups and enables long-term management strategies without the cumulative risks associated with more aggressive interventions.

From Treatment to Control

The key shift with Closebax is not just clinical, but more conceptual. Seborrhoeic dermatitis should not be viewed as a condition that is periodically “treated”. It is a condition that is managed through stabilisation of a dysregulated system. In this context, Closebax becomes more than a product, it becomes a tool for:

• First-line management in mild to moderate cases
• Adjunctive support alongside prescription therapies
• Maintenance to reduce relapse frequency and severity
• Long-term control in patients with chronic or recurrent disease

This approach aligns far more closely with how the condition behaves in reality.

A Strategic Opportunity for Clinics

For clinics, seborrhoeic dermatitis represents a significant but often underutilised opportunity.

It is:

• Highly prevalent
• Frequently recurrent
• Poorly managed in many patients
• A source of ongoing frustration and reduced quality of life

By adopting a system-based approach, centred on microbiome and sebum normalisation, clinics can reposition themselves from providers of short-term relief to providers of long-term control.

This not only improves patient outcomes, but also creates a more consistent and sustainable clinical model.

Final Perspective

Seborrhoeic dermatitis is not a simple fungal infection. It is a manifestation of imbalance within the sebaceous–microbial–inflammatory axis of the skin. Closebax does not attempt to override this system, but works within it,

and in doing so, it allows clinicians to move beyond suppression and towards something far more valuable

Control.

SkinMed Positioning Statement

At SkinMed, we focus on treating the underlying biology of common dermatoses, recognising that conditions such as seborrhoeic dermatitis, acne, and rosacea are not isolated diseases, but interconnected expressions of skin system dysfunction.

By blending dermatology with aesthetics, we enable clinics to deliver clinically credible, scalable, and commercially sustainable solutions for the conditions patients present with every day. This draws may new clients in who more often than not move onto aesthetic procedures.